ClinicalTrials.gg
CompletedNCT02306915Updated Nov 9, 2021

PK, PD, Safety and Tolerability of Lipegfilgrastim in Healthy Japanese and Caucasian Participants

A Phase 1 interventional study of lipegfilgrastim in Pharmacokinetics and Pharmacodynamics, sponsored by Merckle GmbH. Completed at 1 site in United Kingdom. Open to participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-11-09.

Sponsored by Merckle GmbH · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
20 Years to 45 Years
Sex
All
01

Study summary

Cohorts of Japanese participants will be enrolled and treated prior to cohorts of Caucasian participants for the sake of matching. Every effort will be made to match Caucasian and Japanese participants on a cohort basis at enrollment. Reasonable effort will be made to maintain balance between male and female participants within the cohorts. There will be no replacement of participants following randomization.

Read the detailed description

Eligible participants will be admitted to the investigational center and after confirming their eligibility will be randomized to receive a single dose of 30, 60, or 100 μg/kg lipegfilgrastim. There will be 11 visits to the investigational center during the study, including a screening visit, 1 inpatient period (through Day 4 post-dose) and 9 ambulatory visits.

Blood samples for PK, PD and immunogenicity analysis will be collected pre-dose and at specified time points post-dose. A mandatory blood sample for pharmacogenetics (PGx) will be collected from all participants. During the study the following safety assessments will be performed: vital signs measurements,physical examinations, record of adverse events, clinical laboratory tests, urinalysis, safety ECG recordings, local tolerability (injection site reactions), overall tolerability, pregnancy testing, spleen sonography, and concomitant medications

02

Conditions studied

  • Pharmacokinetics
  • Pharmacodynamics

Keywords

  • Lipegfilgrastim, Lonquex, Japanese Bridging
03

In context

Lead sponsor

Merckle GmbH is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) ≥18.0 and ≤25 kg/m2.
  • Body weight must be ≥ 50 kg and ≤ 90 kg.
  • Is in good general health as determined by medical history, physical examination, 12-lead electrocardiography (), vital signs and clinical laboratory tests.
  • Subjects are able to read, write and understand English or Japanese; they must be able to understand the requirements of the study and be willing to comply with all trial requirements.
  • Female subjects of must have a negative serum β-human chorionic gonadotropin (β-hCG) test at screening and negative urine pregnancy test at check-in. All subjects must be either surgically sterile (for females that means documented complete hysterectomy, bilateral oophorectomyor bi-tubal ligations; partial hysterectomy is not sufficient), abstinent throughout the study or, if of reproductive capacity and not abstinent, exercising any 2 different forms of highly effective methods with his/her partner during the entire study period.

    o Additional inclusion criteria for Japanese subjects:

  • Subject must be a non-naturalized Japanese citizen and hold a Japanese passport.
  • Subject must have/had 2 Japanese parents and 4 Japanese grandparents who are all non-naturalized Japanese citizens, as confirmed by interview.
  • Subject has been living outside of Japan for 10 years or fewer as confirmed by interview.

    o Additional inclusion criterion for Caucasian subjects:

  • The subject is Caucasian, and confirms by interview that his/her parents and grandparents are Caucasian and none are of Black/African descent, Middle-Eastern descent or Asian descent.
  • -other criteria apply, please contact the investigator for more information

Exclusion criteria

Exclusion Criteria:

  • History of to pegfilgrastim, filgrastim, lenograstim, Escherichia coli derived proteins, or to any (glacial acetic acid, sodium hydroxide, sorbitol, polysorbate 20).
  • Prior exposure to filgrastim, pegfilgrastim or lenograstim or other granulocyte colony stimulating factors (G-CSFs) in clinical development less than 6 months before randomization.
  • Findings of splenomegaly on sonography, defined by splenic length in excess of 12.3 cm (Andrews, 2000; Benter et al, 2011) and clinical judgment.
  • Existence or recent history of persistent pulmonary infiltrates or recent pneumonia, or current symptoms of upper respiratory infection. In the case of pneumonia, subject may be screened 12 weeks following cessation of antibiotic treatment.
  • -other criteria apply, please contact the investigator for more information
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    lipegfilgrastim 30

    Drug: lipegfilgrastim

  • Experimental
    lipegfilgrastim 60

    Drug: lipegfilgrastim

  • Experimental
    lipegfilgrastim 100

    Drug: lipegfilgrastim

Interventions

06

What researchers measure

Primary outcomes

  1. PK: Area under the serum concentration-time curve (AUC), from time 0 to the last measurable concentration (AUC0-t)

    2 hours for visits 3, 9; 1 day for visit 10

    Time frame: Days 1-8, 10, 14, 17, 21

  2. AUC from time 0 extrapolated to infinity (AUC0-∞)

    Time frame: Days 1-8, 10, 14, 17, 21

  3. Maximum observed serum drug concentration (Cmax)

    Time frame: Days 1-8, 10, 14, 17, 21

  4. Time to maximum observed serum drug concentration (tmax)

    Time frame: Days 1-8, 10, 14, 17, 21

  5. The percentage of the extrapolated area to infinity in relation to the total area under the curve (%AUCext)

    Time frame: Visits 3, 9, 10

  6. Apparent serum terminal elimination rate constant (λz)

    2 hours for visits 3, 9; 1 day for visit 10

    Time frame: Days 1-8, 10, 14, 17, 21

  7. Associated elimination half-life (t½)

    Time frame: Days 1-8, 10, 14, 17, 21

  8. Mean residence time (MRT)

    Time frame: Days 1-8, 10, 14, 17, 21

  9. Apparent total body clearance (CL/F)

    Time frame: Days 1-8, 10, 14, 17, 21

  10. Apparent volume of distribution during the terminal phase (Vz/F)

    Time frame: Days 1-8, 10, 14, 17, 21

  11. PD: ANC area over baseline effect curve (ANC AOBEC)

    Time frame: Days 1-8, 10, 14, 17, 21

  12. Maximum measured ANC value after dosing (ANC Cmax)

    Time frame: Days 1-8, 10, 14, 17, 21

  13. Time point at which ANC Cmax is observed (ANC tmax)

    Time frame: Days 1-8, 10, 14, 17, 21

  14. Time (days) until ANC returns to baseline value

    Time frame: Days 1-8, 10, 14, 17, 21

  15. CD34+ area over the baseline effect curve (CD34+ AOBEC)

    Time frame: Days 1-8, 10, 14, 17, 21

  16. Maximum measured CD34+ value after dosing (CD34+ Cmax)

    Time frame: Days 1-8, 10, 14, 17, 21

  17. Time point at which CD34+ Cmax is observed (CD34+ tmax)

    Time frame: Days 1-8, 10, 14, 17, 21

Secondary outcomes

  1. Percentage of Participants with Adverse Events

    Time frame: 28 Days

07

Study locations

1 site
  • Teva Investigational Site 34193
    London, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2014, a primary completion of Mar 2015 and a completion of May 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2014
First posted
Dec 3, 2014
Start
Oct 2014
Primary completionActual
Mar 2015
CompletionActual
May 2015
Last update
Nov 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02306915
Lead sponsor
Merckle GmbH
Responsible party
Sponsor
First posted
Dec 3, 2014
Start date
Oct 2014
Primary completion
Mar 2015
Completion
May 2015
Last update
Nov 9, 2021

Study contacts

Teva Medical Expert, MD
study director · Teva Branded Pharmaceutical Products R&D, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegfilgrastim

Start the discussion